PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 524591

A volume sensor for a pneumatically driven LVAD.

K E Buck·J D Hill·T C Robinson·P Litwak·G Fountain
View original source ↗Export metadata ↓

Abstract

The volume sensor has proven to be a valuable tool in the operation and characterization of our pneumatically driven LVAD. It compensates for the decoupling between driver and LVAD that occurs in pneumatically actuated LVADs due to gas compressibility. Uses to which we have put the volume sensor represent only a small fraction of the potential applications. Additional uses contemplated include: Use as an alternate or backup for the R-wave detection network currently used to achieve synchronization with the natural heart. This could be done by starting the LVAD ejection phase when the filling flow rate drops below a given threshold, indicating that the left ventricle has finished filling the LVAD. Use for feedback for closed loop control of plate motion. Such control could reduce actuation delays without overdriving the LVAD. Use as a diagnostic tool to aid in the study of the LVAD and its interaction with the cardiovascular system. When used in conjunction with information on left ventricular, aortic, and drive pressures, it is possible to determine the resistance, inertia and compliant characteristics of the major elements of the LVAD and the vascular system to which it is joined.

Explore related subjects

Assisted CirculationBlood VolumeElectric Power SuppliesElectronics, MedicalHumansMonitoring, PhysiologicStroke VolumeJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K E Buck, J D Hill, T C Robinson, P Litwak, G Fountain. 1979. A volume sensor for a pneumatically driven LVAD.. https://doi.org/10.1097/00002480-197902500-00047

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Percutaneous endocardial and epicardial ablation of hypotensive ventricular tachycardia with percutaneous left ventricular assist in the electrophysiology laboratory.

Ventricular tachycardia (VT) in the setting of structural heart disease is challenging to treat with percutaneous catheter ablation due to the presence of complex substrate, multiple morphologies, hemodynamic instability, and epicardial circuits. When substrate-based approaches fail, however, it may be impossible to map and ablate hemodynamically unstable arrhythmias. We describe a novel approach to endocardial and epicardial mapping and ablation of hypotensive VT using a percutaneous left ventricular assist device in the electrophysiology laboratory, permitting near-surgical access to cardiac structures.

Assisted Circulation↗
PubMed2006

IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support.

Commercial immunoassays frequently detect anti-PF4/heparin antibodies during mechanical circulatory support (MCS), but only a small minority of patients develops heparin-induced thrombocytopenia (HIT). Whereas platelet functional tests can distinguish between platelet-activating and non-platelet-activating antibodies, commercial PF4-dependent immunoassays do not. Between 2003 and 2004, 113 patients were placed on MCS. Blood samples were obtained on postimplant day 5-7 for analyses by antibody assays and the functional heparin-induced platelet activation (HIPA) assay. Three distinct groups of patient sera were identified: platelet-activating anti-PF4/heparin antibodies (n = 10), non-platelet-activating anti-PF4/heparin antibodies (n = 53), and anti-PF4/heparin antibody negative (n = 50). Patients with platelet-activating antibodies had the highest risk for thromboembolic events (P < 0.005), whereas those with non-platelet-activating antibodies did not differ from antibody negative patients (P = 0.369). The enzyme-immunoassay and column agglutination assays, which cover all immunoglobulin classes, demonstrated adequate sensitivity and negative predictive value; yet, both lacked specificity with respect to the platelet-activating antibodies. If all antibody positive patients were further classified by an IgG-specific anti-PF4/heparin enzyme-immuno assay, specificity for platelet-activating antibodies increased. Whereas IgG-specific optical density (OD) values below 1.0 were likely for non-platelet-activating anti-PF4/heparin antibodies, higher values were progressively predictive for pathogenic platelet activation. The probability of the development of clinical HIT also increased steeply. In conclusion, platelet-activating anti-PF4/heparin antibodies are relatively common (about 9%) in patients on MCS and are associated with significantly higher thrombotic event rates. Low IgG-specific OD values (< 1.0) in the enzyme-immunoassay indicate low likelihood for the presence of platelet-activating antibodies. These results justify further validation so that anticoagulation during MCS becomes safer and adequate.

Assisted Circulation↗